Veracyte, Inc. (VCYT) Stock forecasts
Argus recently issued a report on Veracyte Inc. (VCYT), a genomic diagnostics company. The report, dated April 29, 2026, includes an earnings estimate and a current price of $25.04 for VCYT. The company focuses on providing clinicians with insights for cancer diagnosis and treatment.
VCYT: Decipher resets to steadier growth as evidence and bladder launches drive the next expansion
Veracyte (VCYT) expects Decipher annual tests to normalize at 12,000–15,000, driven by physician growth and new evidence. The company's 2027 priorities include expanding sales capacity, launching new bladder data and products, and increasing Prosigna volume. This outlook is based on Veracyte's presentation at the Jefferies Global Healthcare Conference on November 18, 2026.
Form 4 Veracyte Inc: Jens Holstein (Director) For: 14 September By Investing.com
This article reports on a Form 4 filing for Veracyte Inc, indicating that Jens Holstein, a director, made a transaction on September 14. The piece briefly mentions the stock symbol VCYT and provides the publication date. No further details about the nature of the transaction are included.
Form 4 Veracyte Inc: Jens Holstein (Director) For: 14 September By Investing.com
This article reports on a Form 4 filing for Veracyte Inc., indicating that director Jens Holstein made a transaction on September 14. The filing was published on November 15, 2026, and the article notes Veracyte's stock symbol as VCYT.
Veracyte director Jens Holstein sells $204,747 in company stock By Investing.com
Jens Holstein, a director at Veracyte, Inc. (NASDAQ:VCYT), sold 5,000 shares of company stock worth $204,747 on September 14, 2026, through a pre-arranged trading plan. Following this transaction, Holstein holds 27,471 shares. Despite the sale, which occurred at prices significantly higher than current trading levels, InvestingPro analysis suggests Veracyte is undervalued, with its stock down 42% year-to-date, trading at $24.33.
Form 4 Veracyte Inc: Jens Holstein (Director) For: 14 September By Investing.com
This article reports a Form 4 filing for Veracyte Inc, indicating that Director Jens Holstein made a transaction on September 14th. The brief notice provides the company stock symbol VCYT and notes a slight decrease in its value.
Form 4 Veracyte Inc: Jens Holstein (Director) For: 14 September By Investing.com
This article from Investing.com reports a Form 4 filing for Veracyte Inc, indicating that Director Jens Holstein was involved in a transaction on September 14. The specific details of the transaction are not provided in the snippet, but it highlights insider trading activity for the company (VCYT).
Veracyte (VCYT) Stock Looks About Right After Cut Prostate Test Outlook
Veracyte's stock price has fallen by over 50% in the last 5 years, and its recent guidance cut for the Decipher Prostate test, coupled with a US$100m share repurchase, has prompted a re-evaluation of its valuation. The stock currently trades at a P/E of 15.5x, which is slightly below the biotech sector average, aligning closely with the Fair Ratio benchmark. Analysts' consensus suggests the stock could be 59% undervalued, focusing on the company's expanding cancer diagnostics portfolio and market penetration.
An amended ownership report places Artisan’s Veracyte (VCYT) stake at 5% or less.
Artisan Partners Asset Management Inc. and its affiliated entities have filed an amended Schedule 13G/A, reporting a beneficial ownership of 2,312,149 Veracyte (VCYT) common shares, representing 2.9% of the class as of September 30, 2026. This updated filing indicates their stake is 5% or less. The reporting persons collectively hold shared voting authority over 2,200,290 shares and shared dispositive authority over 2,312,149 shares.
Veracyte (VCYT) Shares Dropped, So What Is Driving Attention Now?
Veracyte (VCYT) recently announced third-quarter results, a slight reduction in full-year revenue guidance, and a US$100 million buyback authorization, leading to a significant 7.2% drop in its share price. Despite the short-term negative reaction, with the stock down 52.2% over the past week and 43.2% year-to-date, analysts on Simply Wall St assess Veracyte as 60% undervalued with a fair value of $59.73 compared to its last close of $24.06. The company's pipeline momentum, including five major product launches and a pivotal clinical study expected to complete in 18 months, is seen as a long-term growth driver, though execution risks and reimbursement decisions remain concerns.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
Levi & Korsinsky, LLP has announced an investigation into potential securities law violations involving Veracyte, Inc. (NASDAQ: VCYT). This comes after Veracyte's third-quarter report revealed that "Decipher Prostate volume was below our expectations" and full-year 2026 revenue guidance was narrowed due to further slashed Decipher Prostate annual volume projections. The firm is encouraging investors who have incurred losses to submit their information for a no-cost review.
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations on behalf of investors in Veracyte, Inc. (NASDAQ: VCYT). This investigation comes after Veracyte lowered its full-year 2026 revenue guidance, partly due to lower-than-expected Decipher Prostate test volumes, causing its shares to drop by nearly 50%. SBS is inviting shareholders who suffered losses to participate in the investigation.
Veracyte Shares Fall 56% After Updating 2026 Revenue Outlook
Veracyte shares plummeted 56% after the company announced its third-quarter results and updated its 2026 revenue outlook. The cancer-focused molecular diagnostics company saw its stock slide $29.18 to $23.34 during Thursday's trading session.
Tracking Cathie Wood: Adds Over 510K Veracyte, 390K SpaceX; Trims CoreWeave, 410K+ Broadcom
Cathie Wood's ARK Invest has rebalanced its portfolio, shifting capital from compute infrastructure and traditional semiconductors to high-elasticity fields like precision medicine, AI embodied intelligence, and space exploration. Key buys include Veracyte, SpaceX, and Rocket Lab, while significant trims were made in CoreWeave, Broadcom, and BYD Company ADR. This strategy emphasizes "selection over breadth" within disruptive innovation.
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
Veracyte (VCYT) reported Q3 2026 adjusted earnings of $0.51 per share and revenues of $151.8 million, exceeding consensus estimates. Despite the earnings beat, the company lowered its annual sales outlook due to slower-than-expected growth in Decipher Prostate testing. Veracyte plans to increase commercial spending and expand its offerings in breast and bladder cancer.
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
SueWallSt has announced an investigation into Veracyte, Inc. (NASDAQ: VCYT) following a significant drop in its share price. The decline occurred after the company's November 4, 2026 report revealed that Decipher Prostate test volumes were below expectations and full-year 2026 revenue guidance was lowered. The investigation concerns potential securities law violations related to the company's statements about the growth outlook for its Decipher Prostate test.
Veracyte, Inc. Stock 12‑Month Price Target Cut to $56.91, Implies 8% Upside
Veracyte, Inc. (VCYT) has seen its average 12-month price target reduced from $57.82 to $56.91 by analysts, despite forecasts ranging broadly from $34 to $69 per share. Based on the Nov. 4 closing price, this updated target suggests an 8% potential upside for the stock. The consensus rating from 13 analysts remains a "Buy," with 11 recommending Buy and 2 recommending Hold.
Veracyte (VCYT) Q3 2026 Earnings Call Transcript
Veracyte (VCYT) reported robust Q3 2026 financial results with total revenue up 15% year-over-year to $151.8 million, driven by strong testing volume growth. Despite a shortfall in Decipher Prostate volumes, Afirma exceeded expectations, and the company made strategic advancements with the acquisition of Convergent Genomics and the authorization of a $100 million share repurchase program. Management provided preliminary 2027 guidance, projecting mid-single-digit revenue growth and continued investment in commercial expansion and portfolio development.
Why Is Veracyte Stock Sinking Thursday?
Veracyte Inc. (NASDAQ: VCYT) stock fell sharply after reporting weaker-than-expected Decipher Prostate test volume, despite beating third-quarter earnings and revenue estimates. Analysts expressed concerns about the long-term growth of the Decipher test, leading to rating downgrades and price target cuts from some firms, while others maintained Buy ratings. The company also narrowed its fiscal 2026 revenue forecast.
Veracyte plunges 56% after updated 2026 revenue outlook (VCYT:NASDAQ)
Veracyte (VCYT) shares experienced a 56% decline after the company announced its third-quarter results and revised its 2026 revenue outlook. The global molecular-diagnostics company, which focuses on cancer care, saw its stock drop significantly during trading. The article notes that the content was AI-generated based on Seeking Alpha data.
Veracyte stock hits 52-week low at 28.81 USD
Veracyte Inc.'s stock recently hit a 52-week low of $28.29, despite demonstrating significant momentum with a 59% surge over the past six months and a nearly 25% year-to-date gain. The company reported strong Q3 2026 results, exceeding Wall Street expectations, but lowered its full-year revenue guidance due to anticipated lower growth in Decipher volume. Needham subsequently adjusted its price target for Veracyte from $69 to $46, while maintaining a Buy rating.
Veracyte Inc. Latest Results: Narrows FY26 sales guidance to $593m
Veracyte Inc. has narrowed its fiscal year 2026 sales guidance to $590.000 million-$593.000 million, a reduction from the previous upper bound of $596.000 million. This revised upper limit is slightly below the analyst consensus estimate of $593.894 million, suggesting a more conservative outlook. The adjustment indicates that even the company's most optimistic scenarios within the new guidance fall short of market expectations.
Veracyte Inc earnings beat by $0.10, revenue topped estimates
Veracyte Inc (NASDAQ: VCYT) reported strong third-quarter results, beating analyst estimates with an EPS of $0.51 against a projected $0.41, and revenue of $151.75M surpassing the consensus of $147.16M. The company provided FY 2026 revenue guidance between $590.00M and $593.00M, slightly below the analyst consensus of $593.80M. Veracyte's stock has shown robust performance, rising 11.22% over the last 3 months and 25.98% over the past year.
Veracyte Q3 2026 Earnings Call Transcript
Veracyte reported a 15% year-over-year revenue increase to $151.8 million in Q3 2026, driven by strong Afirma performance, although Decipher Prostate volumes were lower than expected. The company plans to expand its urology sales team by 30% and continues to invest in its breast and bladder cancer portfolios, including the recent acquisition of Convergent Genomics. Veracyte adjusted its full-year 2026 revenue guidance to $590-$593 million and anticipates maintaining strong profitability and cash generation.
Veracyte Announces Third Quarter 2026 Financial Results
Veracyte, Inc. announced strong financial results for the third quarter ended September 30, 2026, with total revenue increasing 15% to $151.8 million and testing revenue also up 15% to $146.4 million. The company also announced a new $100 million share repurchase program and provided an updated 2026 total revenue guidance of $590 million to $593 million. Key business highlights include the acquisition of Convergent Genomics, Medicare reimbursement for the Prosigna Breast Risk of Recurrence test, and surpassing 1 million patients served.
Trading Systems Reacting to (VCYT) Volatility
This article analyzes Veracyte Inc. (NASDAQ: VCYT), identifying a near-term neutral sentiment amidst mid and long-term strength, with an exceptional 69.4:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for various time horizons.
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Levi & Korsinsky, LLP has announced an investigation into Veracyte (VCYT) following a significant drop in its stock price. The decline occurred after the company reported on November 4, 2026, that its Decipher Prostate test volume fell short of expectations, leading to reduced financial guidance for 2026. The firm is encouraging investors who experienced losses to report their information for a potential securities class action.
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
The third-quarter 2026 earnings season is revealing a split in the healthcare sector: demand remains strong, but profitability is inconsistent due to factors like pricing pressure and increased operating costs. Despite an anticipated 0.9% decline in medical sector earnings, revenues are expected to rise by 5%. This article identifies four medical stocks—Viatris Inc. (VTRS), Revvity, Inc. (RVTY), Elanco Animal Health Incorporated (ELAN), and Veracyte, Inc. (VCYT)—that possess favorable earnings indicators and business trends, suggesting they might outperform consensus expectations in their upcoming Q3 reports.
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Wygant Jonathan
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Jonathan Wygant, an Officer at Veracyte. The article content provided is simply "Document", indicating that the full details of the transaction are contained within the linked or referenced Form 4, which reports changes in ownership of company stock by insiders.
Form 4 Veracyte Inc: Jonathan Wygant (VP, Chief Accounting Officer) For: 28 October By Investing.com
This article reports on a Form 4 filing for Veracyte Inc., detailing an insider transaction by Jonathan Wygant, VP and Chief Accounting Officer, on October 28. The stock symbol VCYT is noted to be down 4.14%.
Form 4 Veracyte Inc: Jonathan Wygant (VP, Chief Accounting Officer) For: 28 October
This article reports on a Form 4 filing for Veracyte Inc, indicating insider transaction activity by Jonathan Wygant, the VP and Chief Accounting Officer. The filing pertains to actions taken on October 28. The brief update is sourced from Investing.com and is part of their financial market news coverage.
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. announced its participation in three upcoming investor conferences in November 2026: the UBS Global Healthcare Conference, Jefferies Global Healthcare Conference, and Stephens Annual Investment Conference. Live audio webcasts of these presentations will be available on Veracyte's investor relations website, with replays accessible for 90 days. The company, a leading cancer diagnostics firm, will discuss its molecular tests and Diagnostics Platform aimed at transforming cancer care.
Form 4 Veracyte Inc: Jonathan Wygant (VP, Chief Accounting Officer) For: 28 October
This article reports on a Form 4 filing for Veracyte Inc, indicating insider transaction activity by Jonathan Wygant, the VP and Chief Accounting Officer. The filing pertains to transactions that occurred on October 28th. The specific details of the transaction are not provided in this brief announcement.
Veracyte, Inc. (VCYT) Seasonal returns chart
The article provides a seasonal returns chart for Veracyte, Inc. (VCYT), showing the average monthly price return for the stock from 2016 to 2026. As of October 29, the stock was trading at 52.17 USD, up 3.70% from the close.
Veracyte, Inc. (VCYT) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for Veracyte, Inc. (VCYT), showing average monthly price returns from 2016 to 2026. As of October 29, 2026, VCYT's stock price was $52.17, with a daily increase of 3.70%. The chart provides historical seasonality data for various timeframes.
Tax withholding, not a sale: Veracyte (VCYT) officer Wygant retains 41,920 shares.
Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc. (VCYT), had 1,306 common shares withheld on October 28, 2026, to cover tax withholding obligations related to restricted stock unit vesting. This was not a sale, and Wygant continues to hold 41,920 shares directly after the transaction. The shares were valued at $50.31 each.
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. announced its participation in three upcoming investor conferences in November 2026: the UBS Global Healthcare Conference, the Jefferies Global Healthcare Conference, and the Stephens Annual Investment Conference. The company, a leading cancer diagnostics firm, will host fireside chats at each event. Live audio webcasts and replays of these presentations will be available on Veracyte's investor relations website.
A director exercised $35.30 options and sold Veracyte (VCYT) shares at $47 and $50.
Veracyte, Inc. (VCYT) director Jens Holstein exercised options for 15,000 common shares in total across two dates (September 24, 2026, and October 27, 2026) at an exercise price of $35.30 per share. Concurrently, he sold 7,500 shares at $47.00 per share on September 24, 2026, and another 7,500 shares at $50.00 per share on October 27, 2026. All transactions were made under a Rule 10b5-1 plan adopted on June 12, 2026, with the September transactions being reported late due to an administrative error.
Veracyte | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for Veracyte. Rule 144 provides a safe harbor for the resale of restricted and controlled securities without registration under the Securities Act of 1933. This notice indicates an intent to sell shares, likely by an affiliate or an individual holding restricted stock.
Veracyte's Third Raise Meets A Skeptical Crowd As Prosigna Launch Faces First Test
Veracyte Inc. is facing skepticism ahead of its third-quarter earnings report despite management raising its full-year revenue outlook twice. Analysts' full-year consensus revenue still sits below the low end of the company's current guidance, creating a mismatch that the upcoming report on November 4th will address. Key factors include the performance of its core Decipher and Afirma tests, and the initial traction of its new Prosigna breast cancer test launch, which currently lacks Medicare reimbursement.
Director Karin Eastham proposes selling 14,850 Veracyte (VCYT) shares.
Veracyte, Inc. (VCYT) director Karin Eastham has filed a Form 144 proposing to sell 14,850 common shares, valued at approximately $715,770, with an approximate sale date of October 27, 2026. The proposed sale includes shares from both stock-option exercises and restricted stock units, with Morgan Stanley Smith Barney LLC named as the broker. The filing details the acquisition of these securities and confirms that no other securities were sold during the past three months by the person for whose account the securities are to be sold.
Veracyte’s Decipher May Guide Therapy Intensification But More Study Needed on Predictive Capability
A new study presented at ESMO suggests that Veracyte's Decipher test could be useful in guiding therapy intensification for prostate cancer, but further research is required to fully understand its predictive capabilities. The study aimed to shed light on both the prognostic and predictive aspects of the Decipher test. This implies that while the test shows promise in indicating patient outcomes, its ability to predict treatment response needs more investigation.
Veracyte, Inc. Estimates – NASDAQ:VCYT
This page on TradingView provides financial estimates and data for Veracyte, Inc. (VCYT) listed on the Nasdaq Stock Market. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Veracyte announced new data from a Phase III STAMPEDE trial showing its Decipher Prostate Genomic Classifier can predict the benefit of adding abiraterone to androgen deprivation therapy (ADT) for men with very high-risk nonmetastatic prostate cancer. The analysis indicates that patients with higher Decipher scores experienced greater benefit from abiraterone, reducing distant metastasis events significantly. These findings provide critical predictive evidence to help physicians and patients make more informed treatment decisions, bolstering Decipher's established role in prostate cancer risk assessment.
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com
This article reports on a Form 4 filing for Veracyte Inc., indicating that Director Muna Bhanji was involved in a transaction on October 19. The brief notice from Investing.com highlights this insider trading activity.
Veracyte director Muna Bhanji sells $81,456 in company stock By Investing.com
Muna Bhanji, a director at Veracyte, Inc. (NASDAQ: VCYT), sold 1,864 shares of company stock for a total of $81,456 on October 19, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Ms. Bhanji retains 40,854 shares of Veracyte common stock, while recent company news includes strong Q2 2026 earnings, a raised full-year revenue outlook, and the acquisition of Convergent Genomics.
Veracyte director Muna Bhanji sells $81,456 in company stock
Muna Bhanji, a director at Veracyte, Inc. (NASDAQ:VCYT), sold 1,864 shares of company stock for $81,456 on October 19, 2026, as part of a Rule 10b5-1 trading plan. Despite this sale, Ms. Bhanji still directly holds 40,854 shares, and the company recently reported strong second-quarter earnings, exceeding analyst expectations and raising its full-year revenue outlook.
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com
This article reports on a Form 4 filing for Veracyte Inc., detailing insider transactions by Muna Bhanji, a director, on October 19. Form 4 filings are regulatory documents used to disclose changes in beneficial ownership of a company's securities by insiders. The article indicates a specific transaction date but provides no further details on the nature or value of the transaction.
Director Muna Bhanji Sells 1,864 Shares of Veracyte Inc (VCYT)
Muna Bhanji, a Director at Veracyte Inc (VCYT), sold 1,864 shares of the company on October 19, 2026, reducing her holdings to 40,854 shares. This transaction is part of a broader pattern of insider selling at Veracyte, with 34 insider sells and no insider buys over the past year. The stock is considered "Modestly Overvalued" based on its GF Value, and investors are advised to consider test volume growth and reimbursement decisions.
Veracyte Director Muna Bhanji Sells 1,864 Shares at $43.70 Under 10b5-1 Plan
Muna Bhanji, a director at Veracyte, Inc. (NASDAQ:VCYT), sold 1,864 shares of company stock at $43.70 per share on October 19, 2026. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on June 2, 2026. Following the sale, Bhanji directly holds 40,854 common shares of Veracyte.